Press Release Distribution
 

Members Login  |  Register  |  Why Join?   Subscribe to Newsletter Newsletter   RSS Feeds RSS Feeds

Video Releases    |    Pricing & Distribution Plans    |    Today's News    |    News By Category    |    News By Region    |    News By Date    |    Business Directory
All Press Releases for November 29, 2006 »
RSS Feeds RSS Feed     Print this news Printer Friendly     Email this news Email It    Create PDF PDF Version    Bookmark del.icio.us    Diggs



Sleep with Rozerem medication
Rozerem with the active ingredient of Ramelteon has been found working effectively to treat insomnia amongst adults. 
x-small text small text medium text large text


    /24-7PressRelease/ - BINGHAMTON, NY, November 29, 2006 - Rozerem that has been eventually approved by the FDA has shown great results upon the people suffering from insomnia. Before this medicine was approved, other sleeping pills used to have narcotic effects whereby gradually it was reduced with sleeping pills such as Ambien, Lunesta, and Sonata.

Rozerem is found to be the first and only medication prescription for use of insomnia in adults. It is prescribed for the treatment of insomnia with symptoms of difficulty in sleep onset. Rozerem can be prescribed for long-term use because the medication does not shows any evidence of abuse or dependence according to sources.

Rozerem has been found different from other sleep drugs and it targets specific switches of the parts of the brain regulating sleep and thereby flipping these switches called melatonin receptors- Rozerem take the brakes of the natural drives of the body.

"In people who sleep normally, the pineal gland in the brain responds to darkness by producing a hormone called melatonin," Mini says. "This natural melatonin dampens the alerting signal so the sleep load overrides [the waking drive] and allows a person to fall asleep."

Unlike melatonin, which has widespread effects throughout the body, Rozerem sends two specific melatonin-like signals to the brains sleep center. This reduces the alerting signal at the time a person wants to go to sleep.

Rozerem should be taken within 30 minutes before going to bed. It should not be taken with or immediately after a high-fat meal. Engaging in hazardous activities that require concentration (such as operating motor vehicle or heavy machinery) after taking Rozerem should be avoided.

The most common side effects seen with Rozerem were somnolence, dizziness, and fatigue. Rozerem should not be used in people with severe liver abnormalities.

So would not over-the-counter melatonin supplements work as well as Rozerem? No, Mini says. Rozerem has a more potent effect on the sleep center of the brain than melatonin supplements. And unlike the supplement, Rozerem has been tested in well-designed studies.

"If you look at the melatonin data, and the recent NIH consensus panel statement, it says that there is little evidence to support the use of melatonin for the treatment of insomnia," Mini says. "And even at that, the dose needed for sleep promotion is unclear. Strict clinical trials of melatonin have not been done. It is an unregulated supplement."

Please visit our website http://www.benzer11.com/rozerem.html to know more about rozerem medicine and other approved prescriptions.

About Benzer11.com
Benzer11.com has a team of committed pharmacists who are quite professional for their principals and values and lead a team of branch colleagues within their community.


---
Press release service and press release distribution provided by http://www.24-7pressrelease.com


# # #


Read more Press Releases from Olivia Andrews:
Other Press Release Headlines:


Press Release Service & Press Release Distribution News Supplied By 24-7PressRelease.com
Press Release Contact Information:
Olivia Andrews
www.benzer11.com

Writer
Binghamton, NY
New York, New York
USA 13902
Voice: (607) 722-1734
E-Mail: Email us Here
Website: Visit Our Website
Disclaimer:
If you have any questions regarding information in this press release, please contact the person listed in the contact module of this page. Please do not attempt to contact 24-7 Press Release. We are unable to assist you with any information regarding this release. 24-7 Press Release disclaims any content contained in this press release. Please see our complete Terms of Service disclaimer for more information.